每經AI快訊，有投資(zi)者(zhe)在投資(zi)者(zhe)互動平(ping)臺提問：請問貴公司在清肺(fei)排(pai)毒湯(tang)顆粒合作上，與(yu)中國中醫(yi)科學(xue)院中醫(yi)臨(lin)床基礎醫(yi)學(xue)研究所是(shi)什(shen)么關系？雙方(fang)具體分工、職能和(he)各自收益是(shi)什(shen)么？

片(pian)仔(zi)癀(huang)（600436.SH）1月(yue)10日在(zai)投資者(zhe)互動平臺表示，清(qing)肺排(pai)毒(du)顆(ke)粒(li)上市許可持(chi)有人為中(zhong)國(guo)中(zhong)醫(yi)科學(xue)院(yuan)中(zhong)藥(yao)臨(lin)床基(ji)礎醫(yi)學(xue)研(yan)究(jiu)所（以(yi)下簡稱(cheng)臨(lin)基(ji)所），該產(chan)(chan)(chan)品委(wei)托公(gong)(gong)(gong)(gong)(gong)司(si)(si)生(sheng)(sheng)產(chan)(chan)(chan)。臨(lin)基(ji)所與公(gong)(gong)(gong)(gong)(gong)司(si)(si)的(de)合作符合國(guo)家政(zheng)策導(dao)向、符合國(guo)企責任擔(dan)當、符合股東和(he)公(gong)(gong)(gong)(gong)(gong)司(si)(si)利益。 公(gong)(gong)(gong)(gong)(gong)司(si)(si)同意(yi)在(zai)清(qing)肺排(pai)毒(du)顆(ke)粒(li)的(de)小紙盒、說明書、復(fu)合膜、紙箱等包裝材(cai)料上無償(chang)使用(yong)“片(pian)仔(zi)癀(huang)”商標。公(gong)(gong)(gong)(gong)(gong)司(si)(si)僅收取該藥(yao)品的(de)生(sheng)(sheng)產(chan)(chan)(chan)加(jia)工費用(yong)，其金額占公(gong)(gong)(gong)(gong)(gong)司(si)(si)2022年度(du)營業(ye)收入較小，不對公(gong)(gong)(gong)(gong)(gong)司(si)(si)2022年度(du)的(de)財務(wu)狀況和(he)經營業(ye)績產(chan)(chan)(chan)生(sheng)(sheng)重(zhong)大影響。公(gong)(gong)(gong)(gong)(gong)司(si)(si)將(jiang)(jiang)密切關注該藥(yao)品生(sheng)(sheng)產(chan)(chan)(chan)的(de)實際進展(zhan)情況，及時(shi)履行(xing)信(xin)息(xi)披露義(yi)務(wu)。 公(gong)(gong)(gong)(gong)(gong)司(si)(si)積極踐(jian)行(xing)社會責任，將(jiang)(jiang)遵循中(zhong)醫(yi)藥(yao)行(xing)業(ye)發(fa)展(zhan)規律，繼續發(fa)揮(hui)在(zai)中(zhong)藥(yao)制藥(yao)領域的(de)全產(chan)(chan)(chan)業(ye)鏈優(you)勢，為提高(gao)中(zhong)藥(yao)產(chan)(chan)(chan)業(ye)發(fa)展(zhan)活力、加(jia)快中(zhong)醫(yi)藥(yao)高(gao)品質發(fa)展(zhan)、實現中(zhong)醫(yi)藥(yao)傳承創(chuang)新貢獻力量。

(記者 賈運可)

免(mian)責聲明：本文內容與(yu)數據僅供參考，不構(gou)成投資(zi)建(jian)議，使用前核實(shi)。據此(ci)操作，風險自擔(dan)。